Agent company information, Employees & Contact Information

FDA broadens reach of GE HealthCare's amyloid imaging agent Vizamyl in Alzheimer's diagnostics Fierce Biotech

MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells GlobeNewswire

Regeneron reports key phase 3 win in myasthenia gravis, gears up for FDA filing Fierce Biotech

Immutep takes immunotherapy a step further with 'impressive' survival data from Keytruda combo Fierce Biotech

Radiopharma biotech raises $99M series B to test copper-based diagnostic, therapeutic combo Fierce Biotech

Heidelberg to lay off 75% of staff after milestone becomes millstone Fierce Biotech

UPDATED: Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update Fierce Biotech

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset Fierce Biotech

Mineralys' stock jumps as hypertension drug posts double clinical wins Fierce Biotech

Drug based on anti-nausea agent reduces Alzheimer's-advancing astrocytes in mice, biotech says Fierce Biotech

PhaseBio's Brilinta reversal agent wins midstage test as biotech awaits key data on emergency patients Fierce Biotech

AHA: PhaseBio shows Brilinta reversal agent can work where it counts: in an emergency Fierce Biotech

Amyloidosis biotech Attralus scores $116M for handful of treatments, imaging agent Fierce Biotech

CMS opens door to expanded Medicare coverage of diagnostic PET scans for Alzheimer's disease Fierce Biotech

Fierce Biotech Fundraising Tracker '25: Hemab closes $157M series C; Electra shines with $183M Fierce Biotech

Coya touts partnership potential as IL-2 prospect comes through small Alzheimer's study Fierce Biotech

Lantheus acquires Alzheimer’s PET diagnostic developer Meilleur Technologies Fierce Biotech

Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M Fierce Biotech

GE HealthCare claims FDA clearance for amyloid imaging software in Alzheimer’s disease Fierce Biotech

PhaseBio blames COVID-19 disruption as cardiovascular study axed Fierce Biotech

Merck bags options on Evaxion's AI-designed vaccines, offering small upfront and big back end Fierce Biotech

Immutep tries to regain pep as cancer subgroup data show path forward—with a long list of caveats Fierce Biotech

To be better at neuroscience, Biogen will invest outside the therapeutic area Fierce Biotech

FDA delivers approval to Lumicell’s fluorescent system for highlighting residual breast cancer tissue Fierce Biotech

Could a simple dietary supplement treat Alzheimer's? Fierce Biotech

Roche celebrates Pharma Day by buying Regor's CDK inhibitors, regenerative med-focused AntlerA Fierce Biotech

Rodin to launch trial of new imaging agent to visualize synapses in the brain Fierce Biotech

Delimiting and delivering: Promontory co-founder 'can't hire fast enough' as small biotech expands vision Fierce Biotech

Cancer biotech Dispatch unveils with $216M and CAR-T pioneer Carl June as cofounder Fierce Biotech

Bioneex's AI Agent Helped Stanford Founded Emerging Biotech Identify Novel Asset PRWeb

With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer field Fierce Biotech

ALX lays off 30% of staff to pay for more trials of CD47 blocker Fierce Biotech

ContraFect halts phase 3 after antimicrobial fails futility test against MRSA Fierce Biotech

Radiopharma biotech Telix drops $200M Nasdaq IPO plans at last minute Fierce Biotech

JPM25: Eli Lilly strikes $2.5B Scorpion buyout in twist to breast cancer tale Fierce Biotech

Gilead pays $43.5M for early-phase IL-12 prospect from Xilio as biotech reduces head count Fierce Biotech

Eli Lilly rolls the dice, axing psoriasis prospect and pivoting to follow-up 1 year after $2.4B buyout Fierce Biotech

Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D Fierce Biotech

Agenus cell therapy spinoff MiNK inks mark on Wall Street with low-end $40M IPO Fierce Biotech

Cerevel to raise $445M, hit Wall Street via blank check company Fierce Biotech

FierceBiotech's 2017 Fierce 15 Fierce Biotech

Ovid flunks Angelman phase 3, leaving field wide open for rivals Fierce Biotech

In conversation with: Jeremy Levin, CEO of Ovid Therapeutics Fierce Biotech

Zentalis pulls off speedy $165M IPO amid pandemic-driven uncertainty Fierce Biotech

'A slow-moving catastrophe': FDA cuts are like firing all hospital staff except doctors, Janet Woodcock says Fierce Biotech

Angelini lands EU rights to Ovid's phase 3 rare disease drug Fierce Biotech

Proniras launches with BARDA funding to pit migraine drug against nerve agents Fierce Biotech

Incyte drops pair of PD-L1 drugs as part of 2nd pipeline clear-out this year Fierce Biotech

Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed Fierce Biotech

Otsuka pays Akebia $55M to exit anemia pill pacts amid dispute and FDA rejection Fierce Biotech

Blast rocks Russian lab that stores smallpox virus Fierce Biotech

Viking's oral obesity med sails ahead, posting 6.8% weight loss for highest dose in phase 1 Fierce Biotech

The Trump administration called this biotech VC firm a suspicious agent of China. It's run by U.S. citizens statnews.com

GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out Fierce Biotech

With J&J, GSK leading the pack, AbbVie jumps in the multiple myeloma fight with TeneoOne buy Fierce Biotech

ROCK2 agent stops GVHD Nature

Tobira and Korea's Dong-A ST sign $80M diabetes/NASH deal Fierce Biotech

Boston Scientific nixes $230M acquisition of stent maker M.I.Tech, citing regulatory roadblocks Fierce Biotech

Blue Earth Diagnostics sold to Bracco Imaging in $450M deal Fierce Biotech

J&J buys into Bristol-Myers cardiovascular disease program Fierce Biotech

Novo's investment arm gains toehold in diagnostics with £400M deal for testing supplier BBI Fierce Biotech

AbbVie powers CAR-macrophage startup Carisma to $53M A round Fierce Biotech

Realtor Agent in San Diego, CA Leverages Biotech and University Growth to Serve First-Time Homebuyers FinancialContent

Synta Pharmaceuticals Reports Third-Quarter 2010 Financial Results and Clinical Update Fierce Biotech

Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET Fierce Biotech

"Agent Orange" Corn: Biotech Only Winner in Chemical Arms Race as Herbicide Resistant Crops Fail Civil Eats